SecBot SecBot

OPK drug pipeline

OPKO HEALTH, INC. · 2 rated drugs
$1.62
−3.6% 1-day · Nov 16
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
No history
No past FDA events with prices
IV rank
No data
No current options data
Rated drugs
2
2 neutral
Phase 3 trials
0
0 with results posted

Drugs

soonest catalyst first
● neutral
Impact
PhaseApproved (China NMPA)
Time to marketAlready approved and commercializing in China (June 2025 for weight management, September 2025 for type 2 diabetes). No US FDA filing has been announced; US approval is estimated in the 2027-2028 window if Eli Lilly initiates and completes global Phase 3 trials.

mazdutide Updated Nov 6

What to watch

Watch OPKO's quarterly royalty revenue from mazdutide as a gauge of China commercial uptake. Innovent's product revenue grew over 40% YoY in Q3 2026, but OPKO's specific royalty share is not separately disclosed. No near-term binary catalyst exists for this asset; the next potential catalyst would be Eli Lilly announcing a US Phase 3 program or FDA filing, which is not expected before 2027-2028.

Bull case
  • Mazdutide is the world's first approved GLP-1/glucagon dual agonist, a novel mechanism that showed 14-20% weight loss in Phase 3 China trials (GLORY-1 and GLORY-2), potentially differentiating it from single-mechanism competitors.
  • China approved mazdutide for both weight management (June 2025) and type 2 diabetes (September 2025), giving it a large addressable market in a country with high obesity and diabetes prevalence.
  • Innovent reported Q3 2026 product revenue exceeding RMB 4.7 billion (over 40% YoY growth), with mazdutide cited as a key growth driver, suggesting accelerating commercial uptake.
Bear case
  • OPKO is a passive royalty holder, not the developer; Eli Lilly and Innovent control commercialization, pricing and supply, leaving OPKO with no operational influence over mazdutide's success.
  • Royalty revenue is still small: Q4 2025 generated only $4.3 million for OPKO, a negligible contribution relative to the company's overall revenue and operating losses.
  • OPKO has already borrowed $125 million against future mazdutide royalty streams (August 2026), capping total repayment at 1.5x funded, which limits the upside OPKO can capture from the royalty stream.
● neutral
Impact
PhasePhase 1/2a
Time to marketAt least 5-7 years, assuming successful completion of Phase 1/2a, Phase 2, and Phase 3 trials followed by regulatory filing and review.

OPK-8801001 Updated Nov 6

What to watch

OPK-8801001 just began Phase 1/2a dosing on October 27, 2026, so the next meaningful catalyst is initial safety and pharmacodynamic data, likely not for 12+ months. For OPKO Health, the bigger near-term drivers are the Labcorp/BioReference asset sale closing and NGENLA royalty revenue trends. This early-stage program is unlikely to move the stock in the foreseeable future.

Bull case
  • Preclinical data presented at ENDO 2026 showed robust, dose-dependent, sustained IGF-1 suppression in animal models, and the drug reportedly has roughly 20-fold greater in vitro potency versus the standard-of-care pegvisomant.
  • OPK-8801001 targets a clear unmet need: a once-weekly injection versus the current daily pegvisomant regimen, which could improve patient compliance and capture market share.
  • OPKO Health has deep expertise in growth hormone biology through its approved product NGENLA (somatrogon, partnered with Pfizer), and its stabilizer-based technology platform is already clinically validated.
Bear case
  • Phase 1/2a trials have a high failure rate; the drug could fail on safety or fail to show adequate IGF-1 suppression in humans despite promising preclinical data.
  • The acromegaly market already has established therapies including daily pegvisomant (Somavert, Pfizer) and long-acting somatostatin analogs, creating a high bar for a new entrant.
  • OPK-8801001 is a very small program within OPKO Health's broader pipeline; even if successful, it is years from commercialization and unlikely to move the stock near-term.

Other drugs in filings and trials

no drug report yet

Clinical trials

1 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
Calcifediol Oral CapsuleSafety, Efficacy, PK and PD of CTAP101 (Calcifediol) ER Capsules for SHPT in HD Patients VDIPhase 2Terminated · results44Feb 24, 2021